journal
MENU ▼
Read by QxMD icon Read
search

ESMO Open

journal
https://www.readbyqxmd.com/read/30018817/choosing-wisely-in-oncology-necessity-and-obstacles
#1
REVIEW
Piercarlo Saletti, Piero Sanna, Luca Gabutti, Michele Ghielmini
In the last decades, the survival of many patients with cancer improved thanks to modern diagnostic methods and progresses in therapy. Still for several tumours, especially when diagnosed at an advanced stage, the benefits of treatment in terms of increased survival or quality of life are at best modest when not marginal, and should be weighed against the potential discomfort caused by medical procedures. As in other specialties, in oncology as well the dialogue between doctor and patient should be encouraged about the potential overuse of diagnostic procedures or treatments...
2018: ESMO Open
https://www.readbyqxmd.com/read/30018816/indicators-of-integration-at-esmo-designated-centres-of-integrated-oncology-and-palliative-care
#2
David Hui, Nathan I Cherny, Jimin Wu, Diane Liu, Nicola Jane Latino, Florian Strasser
Background: A recent international consensus panel identified 13 major indicators to assess the level of integration between oncology and palliative care. We examined these indicators among European Society for Medical Oncology (ESMO) Designated Centres (ESMO-DCs) of Integrated Oncology and Palliative Care (PC) and determined the centre characteristics associated with greater integration. Methods: This is a preplanned secondary analysis of a recent survey to characterise the structure, processes and outcomes of the palliative care programmes at ESMO-DCs...
2018: ESMO Open
https://www.readbyqxmd.com/read/30018815/patient-reported-outcomes-in-a-phase-ii-north-american-study-of-alectinib-in-patients-with-alk-positive-crizotinib-resistant-non-small-cell-lung-cancer
#3
Sai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, Leena Gandhi, Howard West, Alberto Alejandro Chiappori, Victor Cohen, Gregory J Riely, Vlatka Smoljanovic, Walter Bordogna, Elaine Wright, Kendra Debusk, Ali Zeaiter, Alice T Shaw
Background: In a phase II North American study (NP28761; NCT01871805), the anaplastic lymphoma kinase (ALK) inhibitor alectinib demonstrated both systemic and central nervous system (CNS) efficacy with good tolerability in patients with ALK -positive non-small cell lung cancer. We describe patient-reported outcomes (PROs) from the NP28761 study. Patients and methods: PROs and health-related quality of life (HRQoL) benefits were assessed using two self-administered questionnaires (the European Organisation for Research and Treatment of Cancer 30-Item Quality of Life Questionnaire-Core (EORTC QLQ-C30), and the 13-item EORTC QLQ-lung cancer-specific module) at enrolment and every 6 weeks until week 66, disease progression or death...
2018: ESMO Open
https://www.readbyqxmd.com/read/30018814/triplete-a-randomised-phase-iii-study-of-modified-folfoxiri-plus-panitumumab-versus-mfolfox6-plus-panitumumab-as-initial-therapy-for-patients-with-unresectable-ras-and-braf-wild-type-metastatic-colorectal-cancer
#4
Beatrice Borelli, Roberto Moretto, Sara Lonardi, Andrea Bonetti, Carlotta Antoniotti, Filippo Pietrantonio, Gianluca Masi, Valentina Burgio, Federica Marmorino, Lisa Salvatore, Daniele Rossini, Alberto Zaniboni, Gemma Zucchelli, Angelo Martignetti, Monica Di Battista, Nicoletta Pella, Alessandro Passardi, Alessandra Boccaccino, Francesco Leone, Camilla Colombo, Cristina Granetto, Francesca Vannini, Valentina Angela Marsico, Erika Martinelli, Lorenzo Antonuzzo, Stefano Vitello, Laura Delliponti, Luca Boni, Chiara Cremolini, Alfredo Falcone
Background: FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed that a modified FOLFOXIRI regimen in combination with cetuximab or panitumumab, respectively, achieved high therapeutic activity in RAS and BRAF wild-type patients with an acceptable toxicity profile. Drawing from these considerations, we designed TRIPLETE study aiming at comparing two different chemotherapy backbones (mFOLFOXIRI or mFOLFOX6) in combination with panitumumab in the first-line treatment of patients with RAS and BRAF wild-type metastatic colorectal cancer...
2018: ESMO Open
https://www.readbyqxmd.com/read/30018813/questions-asked-in-the-everyday-practice-immune-checkpoint-inhibitors
#5
John B A G Haanen
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/30018812/2018-esmo-sarcoma-and-gist-symposium-take-home-messages-in-soft-tissue-sarcoma
#6
REVIEW
Anna Maria Frezza, Alex T J Lee, Eran Nizri, Marta Sbaraglia, Robin L Jones, Alessandro Gronchi, Angelo Paolo Dei Tos, Paolo G Casali
The 7th edition of the 'ESMO Sarcoma and GIST Symposium' was held in Milan in February 2018. For the first time, the Symposium brought together representatives from the European Reference Network on rare adult solid cancer (EURACAN) joined by sarcoma experts from the USA, Japan and patient advocacy groups, to share insights and discuss future directions in this rare condition. This commentary will summarise the highlights in soft tissue sarcomas.
2018: ESMO Open
https://www.readbyqxmd.com/read/30018811/phase-i-study-of-trasgex-a-glyco-optimised-anti-her2-monoclonal-antibody-in-patients-with-her2-positive-solid-tumours
#7
Walter Fiedler, Herbert Stoeger, Antonella Perotti, Guenther Gastl, Jens Weidmann, Bruno Dietrich, Hans Baumeister, Antje Danielczyk, Steffen Goletz, Marc Salzberg, Sara De Dosso
Purpose: TrasGEX is a second-generation monoclonal antibody of trastuzumab, glyco-optimised to enhance antibody-dependent cellular cytotoxicity while fully retaining trastuzumab's antigen-binding properties to human epidermal growth factor receptor 2 (HER2). A phase I dose-escalation study was conducted to establish the optimal TrasGEX dose and regimen for phase II studies and to define the safety, pharmacokinetics (PK) and preliminary antitumour activity of TrasGEX. Patients and methods: A total of 37 patients with advanced HER2-positive carcinomas and progressive disease received TrasGEX intravenously every 3 weeks until disease progression in doses of 12-720 mg in a three-plus-three dose escalation design, including an expansion cohort at the highest dose...
2018: ESMO Open
https://www.readbyqxmd.com/read/30018810/potential-new-biomarkers-for-squamous-carcinoma-of-the-uterine-cervix
#8
Peter A van Dam, Christian Rolfo, Rossana Ruiz, Patrick Pauwels, Christophe Van Berckelaer, Xuan Bich Trinh, Jose Ferri Gandia, Johannes P Bogers, Steven Van Laere
Aim: An in silico pathway analysis was performed in an attempt to identify new biomarkers for cervical carcinoma. Methods: Three publicly available Affymetrix gene expression data sets (GSE5787, GSE7803, GSE9750) were retrieved, vouching for a total 9 cervical cancer cell lines, 39 normal cervical samples, 7 CIN3 samples and 111 cervical cancer samples. An Agilent data set (GSE7410; 5 normal cervical samples, 35 samples from invasive cervical cancer) was selected as a validation set...
2018: ESMO Open
https://www.readbyqxmd.com/read/30018809/postoperative-chemotherapy-with-single-agent-fluoropyrimidines-after-resection-of-colorectal-cancer-liver-metastases-a-meta-analysis-of-randomised-trials
#9
Davide Mauri, George Zarkavelis, Panagiotis Filis, Lampriani Tsali, Georgia Zafeiri, Alexandra Papadaki, Amalia Vassou, Christos Georgopoulos, George Pentheroudakis
Surgical resection is the only option of cure for patients with metastatic colorectal cancer. Risk of recurrence after metastasectomy is around 75%. Use of adjuvant chemotherapy after metastasectomy is controversial. Aim: To address whether adjuvant systemic therapy after colorectal cancer metastasectomy offers any survival benefit compared with surgery alone. Methods: Systematic review of literature and meta-analysis of all available randomised evidence. Relative hazards (RHs) were summarised across trials and heterogeneity was assessed with the Q and I2 statistics...
2018: ESMO Open
https://www.readbyqxmd.com/read/29942670/practical-issues-of-biomarker-assisted-targeted-therapy-in-precision-medicine-and-immuno-oncology-era
#10
Dae Ho Lee
The concept of precision medicine is not new, as multiplex and very sensitive methods, or next-generation sequencing and matched targeted cancer therapies, have come to clinical practice. Substantial progress has been made from the discovery to the development and clinical application of biomarkers and matched targeted therapies. However, there still remain many challenges and issues to be overcome in each step, from acquisition of tumour tissues through validation of biomarkers to the final decision on targeted therapy...
2018: ESMO Open
https://www.readbyqxmd.com/read/29942669/incidence-of-cetuximab-related-infusion-reaction-in-head-and-neck-cancer-patients-may-we-predict-it
#11
EDITORIAL
Marco C Merlano, Ornella Garrone
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29942668/in-the-literature-june-2018
#12
José Alejandro Pérez-Fidalgo, Valentina Gambardella, Andrés Cervantes
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29942667/shortening-adjuvant-chemotherapy-in-stage-iii-colon-cancer-are-we-ready-for-a-change
#13
EDITORIAL
Desamparados Roda, Fortunato Ciardiello, Andrés Cervantes
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29942666/phase-ib-ii-trial-evaluating-the-safety-tolerability-and-immunological-activity-of-durvalumab-medi4736-anti-pd-l1-plus-tremelimumab-anti-ctla-4-combined-with-folfox-in-patients-with-metastatic-colorectal-cancer
#14
Jean-David Fumet, Nicolas Isambert, Alice Hervieu, Sylvie Zanetta, Jean-Florian Guion, Audrey Hennequin, Emilie Rederstorff, Aurélie Bertaut, Francois Ghiringhelli
Background: 5-Fluorouracil plus irinotecan or oxaliplatin alone or in association with target therapy are standard first-line therapy for metastatic colorectal cancer (mCRC). Checkpoint inhibitors targeting PD-1/PD-L1 demonstrated efficacy on mCRC with microsatellite instability but remain ineffective alone in microsatellite stable tumour. 5-Fluorouracil and oxaliplatin were known to present immunogenic properties. Durvalumab (D) is a human monoclonal antibody (mAb) that inhibits binding of programmed cell death ligand 1 (PD-L1) to its receptor...
2018: ESMO Open
https://www.readbyqxmd.com/read/29942665/role-of-chemotherapy-in-resectable-liver-metastases-from-colorectal-cancer-food-for-thought-from-pooled-evidence
#15
EDITORIAL
Davide Mauri, Panagiotis Filis, Lampriani Tsali, George Zarkavelis, George Pentheroudakis
No abstract text is available yet for this article.
2018: ESMO Open
https://www.readbyqxmd.com/read/29942664/single-agent-parp-inhibitors-for-the-treatment-of-patients-with-brca-mutated-her2-negative-metastatic-breast-cancer-a-systematic-review-and-meta-analysis
#16
Francesca Poggio, Marco Bruzzone, Marcello Ceppi, Benedetta Conte, Samuel Martel, Christian Maurer, Marco Tagliamento, Giulia Viglietti, Lucia Del Mastro, Evandro de Azambuja, Matteo Lambertini
Single-agent poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) have been approved as the first targeted therapy available for patients with BRCA -mutated HER2-negative metastatic breast cancer. This meta-analysis aimed to better evaluate activity, efficacy and safety of single-agent PARPi in this population. A systematic search of Medline, Embase and conference proceedings up to 31 January 2018 was conducted to identify randomised controlled trials (RCTs) investigating single-agent PARPi versus monochemotherapy in patients with BRCA -mutated HER2-negative metastatic breast cancer...
2018: ESMO Open
https://www.readbyqxmd.com/read/29942663/clonal-evolution-of-colorectal-cancer-in-a-patient-with-serially-resected-metastases-and-liquid-biopsies-a-case-report-and-discussion-of-the-literature
#17
Myrto Kastrisiou, George Zarkavelis, Eleftherios Kampletsas, Eleni Panopoulou, Anna Goussia, George Nasioulas, Eirini Papadopoulou, Christina Tsaousi, George Pentheroudakis
Background: Metastatic colorectal cancer represents a striking example of clonal heterogeneity and tumour evolution, which generates acquired resistance to therapy. Once hard to perform, the study of clonal heterogeneity is now significantly aided by the use of liquid biopsies. Method: We herein report a case of a patient with colorectal cancer and serial development of multiple metastases which were all resected and genotyped. A rare point mutation was identified in the primary tumour (but not in any of the organ metastatic sites), as well as in the first and the last out of three consecutive liquid biopsies...
2018: ESMO Open
https://www.readbyqxmd.com/read/29942662/30-immunotherapy-in-advanced-nsclc-from-the-tsunami-of-therapeutic-knowledge-to-a-clinical-practice-algorithm-results-from-an-international-expert-panel-meeting-of-the-italian-association-of-thoracic-oncology-aiot
#18
REVIEW
Filippo de Marinis, Fortunato Ciardiello, Paul Baas, Lucio Crinò, Giuseppe Giaccone, Francesco Grossi, Matthew D Hellmann, Tony S K Mok, Hervè Lena, Luis Paz-Ares, Delvys Rodriguez-Abreu, Joachim Von Pavel, Cesare Gridelli
Although lung cancer remains the leading cause of death from cancer worldwide, the advent of immunotherapy is changing the survival of patients affected by non-small cell lung cancer (NSCLC). A multitude of clinical trials are evaluating different immune checkpoints inhibitors in this new field of thoracic oncology. At the beginning of the immunotherapy era, nivolumab, pembrolizumab and atezolizumab showed high efficacy in patients with advanced NSCLC in second-line setting, receiving approvals for clinical practice...
2018: ESMO Open
https://www.readbyqxmd.com/read/29942661/empirical-antimicrobial-treatment-in-haemato-oncological-patients-with-neutropenic-sepsis
#19
REVIEW
Matthias Gerhard Vossen, Christopher Milacek, Florian Thalhammer
Neutropenic sepsis in haemato-/oncological patients is a medical emergency, as infections may show a fulminant clinical course. Early differentiation between sepsis and febrile neutropenic response often proves to be challenging. To assess the severity of the illness, different tools, which are discussed in this article, are available. Once the diagnosis has been established, the correct use of early empirical antibiotic and antifungal treatment is key in improving patient survival. Therefore, profound knowledge of local resistance patterns is mandatory and carefully designed antibiotic regimens have to be established in cooperation with local microbiologists or infectious diseases specialists...
2018: ESMO Open
https://www.readbyqxmd.com/read/29862052/initial-experience-with-the-bispecific-anti-cea-anti-cd3-antibody-and-its-expected-impact-on-future-treatment-for-patients-with-colorectal-cancer
#20
journal
journal
53848
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"